A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

Trial Profile

A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs ALN CC5 (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2017 According to an Alnylam Pharmaceuticals media release, initial clinical proof of concept data is expected in late 2018.
    • 14 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top